A Randomized Double-Blind Parallel-Group Study to Evaluate the Long-Term Effects of a Medical Device Containing 0.3% Octatrienoic Acid in the Treatment of Grade III Actinic Keratosis.
Graziella BabinoStefano CaccavaleDaniela PintoAnna TrinkGiammaria GiulianiFabio RinaldiGiuseppe ArgenzianoPublished in: Dermatology and therapy (2021)
The medical device has demonstrated good efficacy in the reduction of visible AKs, encouraging its use.